Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients
Authors:
- 1 July 2018
- journal article
- research article
- Published by Elsevier in Journal of Autoimmunity
- Vol. 91, 55-60
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Biological treatments in giant cell arteritis & Takayasu arteritisEuropean Journal of Internal Medicine, 2018
- Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)Annals of the Rheumatic Diseases, 2018
- Efficacy of Biological-Targeted Treatments in Takayasu ArteritisCirculation, 2015
- Th1 and Th17 Cytokines Drive Inflammation in Takayasu ArteritisArthritis & Rheumatology, 2015
- Tocilizumab in refractory Takayasu arteritis: A case series and updated literature reviewAutoimmunity Reviews, 2013
- Diagnostic Features, Treatment, and Outcomes of Takayasu Arteritis in a US Cohort of 126 PatientsMayo Clinic Proceedings, 2013
- Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritisRheumatology, 2013
- Limitations of therapy and a guarded prognosis in an american cohort of takayasu arteritis patientsArthritis & Rheumatism, 2007
- Treatment of glucocorticoid‐resistant or relapsing takayasu arteritis with methotrexateArthritis & Rheumatism, 1994
- Takayasu ArteritisAnnals of Internal Medicine, 1994